Rituximab Injection

DRUG14 trials

Sponsors

Papworth Hospital NHS Foundation Trust, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Canadian Cancer Trials Group, Chinese University of Hong Kong, Hopital Foch

Conditions

Acute Lymphoblastic Leukemia, in RelapseCD20 Positive B Cell NHLDermatologic DiseaseDiffuse Large B-cell LymphomaFollicular LymphomaIgA VasculitisInflammationIschemic Heart Disease

Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Active, not recruitingNCT04161248

Canadian Cancer Trials GroupLymphoma, B-Cell

Start: 2020-09-02End: 2026-12-31Updated: 2026-06-24

Phase 1

Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study

CompletedNCT03072199

Papworth Hospital NHS Foundation TrustInflammation, Ischemic Heart Disease, Myocardial Infarction

Start: 2017-06-01End: 2021-05-01Updated: 2021-09-14

Pharmacokinetics, Efficacy and Safety of the 304 Injection

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.CD20 Positive B Cell NHL

Start: 2018-12-18End: 2019-10-31Target: 60Updated: 2019-06-10

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-12-01End: 2025-11-05Target: 75Updated: 2023-12-11

Phase 2

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

CompletedNCT04224571

Chinese University of Hong KongAcute Lymphoblastic Leukemia, in Relapse

Start: 2018-09-14End: 2023-02-15Updated: 2023-08-30

Phase 3

Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis

CompletedNCT05329090

Hopital FochIgA Vasculitis

Start: 2022-03-11End: 2026-01-13Updated: 2026-06-11

Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)

RecruitingNCT06341205

Centre Hospitalier Universitaire de NiceMembranous Nephropathy

Start: 2025-02-04End: 2031-09-30Target: 120Updated: 2026-06-22

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT06792253

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2025-01-06End: 2029-06-30Target: 416Updated: 2026-08-19

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

RecruitingNCT06929624

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Diffuse Large B-cell Lymphoma

Start: 2025-04-24End: 2028-01-01Target: 280Updated: 2026-07-01

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Not yet recruitingNCT07187960

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Follicular Lymphoma

Start: 2025-11-30End: 2029-02-28Target: 228Updated: 2025-09-23

A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Not yet recruitingNCT07753369

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymppho

Start: 2026-08-01End: 2030-12-01Target: 128Updated: 2026-08-11

Phase 4

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus

RecruitingNCT05898308

University Hospital, RouenDermatologic Disease, Pemphigus

Start: 2024-12-04End: 2032-05-01Target: 133Updated: 2026-02-20

Unknown Phase

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruitingNCT05990985

The First Hospital of Jilin UniversityDiffuse Large B-cell Lymphoma

Start: 2023-09-01End: 2026-08-01Target: 20Updated: 2023-08-18

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Active, not recruitingNCT07071246

Tang-Du HospitalTreatment

Start: 2022-08-01End: 2027-07-31Target: 30Updated: 2025-07-17

Related Papers

Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.

Journal of Clinical Oncology2025-05-281 citations

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial

BMJ Open2025-04-013 citations

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.

2022-12-0112 citations

Rituximab in patients with acute ST-elevation myocardial infarction: an experimental medicine safety study

Cardiovascular Research2021-03-2963 citations